Meeting
2017 ASCO Annual Meeting
Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer.
Authors
Laura Williams Goff
Vanderbilt University Medical Center, Nashville, TN
Laura Williams Goff , Nilofer Saba Azad , Stacey Stein , Jennifer Whisenant , Ulka N. Vaishampayan , Howard S. Hochster , Roisin M. Connolly , Amy M. Weise , Patricia LoRusso , Wael El-Rifai , Jordan Berlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02319018
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2593)
DOI
10.1200/JCO.2017.35.15_suppl.2593
Abstract #
2593
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2016 Gastrointestinal Cancers Symposium
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2023 ASCO Annual Meeting
A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non–small-cell lung cancer.
First Author: Sarah B. Goldberg